ABSTRACT
Adenosine triphosphate (ATP) is well-known as a universal source of energy in living cells. Less known is that this molecule has a variety of important signaling functions: it activates a variety of specific metabotropic (P2Y) and ionotropic (P2X) receptors in neuronal and non-neuronal cell membranes. So, a wide variety of signaling functions well fits the ubiquitous presence of ATP in the tissues. Even more ubiquitous are protons. Apart from the unspecific interaction of protons with any protein, many physiological processes are affected by protons acting on specific ionotropic receptors-acid-sensing ion channels (ASICs). Both protons (acidification) and ATP are locally elevated in various pathological states. Using these fundamentally important molecules as agonists, ASICs and P2X receptors signal a variety of major brain pathologies. Here we briefly outline the physiological roles of ASICs and P2X receptors, focusing on the brain pathologies involving these receptors.
Subject(s)
Acid Sensing Ion Channels , Adenosine Triphosphate , Brain Diseases , Protons , Receptors, Purinergic P2X , Humans , Acid Sensing Ion Channel Blockers/pharmacology , Acid Sensing Ion Channels/metabolism , Adenosine Triphosphate/metabolism , Alzheimer Disease , Amyotrophic Lateral Sclerosis , Brain Diseases/epidemiology , Brain Diseases/metabolism , Brain Diseases/pathology , Chronic Pain , COVID-19 , Epilepsy , Huntington Disease , Ischemic Stroke , Mental Disorders , Multiple Sclerosis , Neurodegenerative Diseases , Neuroinflammatory Diseases , Parkinson Disease , Receptors, Purinergic P2X/metabolism , AnimalsABSTRACT
Here, we describe a molecular switch associated with opioid receptors-linked signalling cascades that provides a dual opioid control over P2X3 purinoceptor in sensory neurones. Leu-enkephalin inhibited P2X3-mediated currents with IC50 ~10 nM in ~25% of small nociceptive rat dorsal root ganglion (DRG) neurones. In contrast, in neurones pretreated with pertussis toxin leu-enkephalin produced stable and significant increase of P2X3 currents. All effects of opioid were abolished by selective µ-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), nonselective inhibitor naloxone, and by PLC inhibitor U73122. Thus, we discovered a dual link between purinoceptors and µ-opioid receptors: the latter exert both inhibitory (pertussis toxin-sensitive) and stimulatory (pertussis toxin-insensitive) actions on P2X3 receptors through phospholipase C (PLC)-dependent pathways. This dual opioid control of P2X3 receptors may provide a molecular explanation for dichotomy of opioid therapy. Pharmacological control of this newly identified facilitation/inhibition switch may open new perspectives for the adequate medical use of opioids, the most powerful pain-killing agents known today.
Subject(s)
Receptors, Opioid, mu/metabolism , Receptors, Purinergic P2X3/metabolism , Sensory Receptor Cells/metabolism , Analgesics, Opioid/pharmacology , Animals , Dipeptides/pharmacology , Naloxone/pharmacology , Rats, Wistar , Sensory Receptor Cells/drug effectsABSTRACT
P2X3 purinoreceptors expressed in mammalian sensory neurons play a key role in several processes, including pain perception. From the venom of the Central Asian spider Geolycosa sp., we have isolated a novel peptide, named purotoxin-1 (PT1), which is to our knowledge the first natural molecule exerting powerful and selective inhibitory action on P2X3 receptors. PT1 dramatically slows down the removal of desensitization of these receptors. The peptide demonstrates potent antinociceptive properties in animal models of inflammatory pain.
